Co-Diagnostics (NASDAQ:CODX) Raised to Hold at Wall Street Zen

Co-Diagnostics (NASDAQ:CODX) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Other equities research analysts have also issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Co-Diagnostics in a report on Thursday, October 30th. D. Boral Capital restated a “buy” rating and set a $90.00 price target on shares of Co-Diagnostics in a research report on Tuesday, October 28th. HC Wainwright reaffirmed a “neutral” rating on shares of Co-Diagnostics in a research note on Monday, November 24th. Finally, Maxim Group downgraded Co-Diagnostics from a “buy” rating to a “hold” rating in a report on Friday, January 23rd. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $55.00.

Co-Diagnostics Price Performance

NASDAQ CODX opened at $2.45 on Friday. Co-Diagnostics has a 1 year low of $2.20 and a 1 year high of $46.50. The stock has a market capitalization of $5.53 million, a PE ratio of -0.08 and a beta of 1.33. The company’s 50 day simple moving average is $4.42 and its two-hundred day simple moving average is $8.69.

Institutional Trading of Co-Diagnostics

Large investors have recently modified their holdings of the business. Jane Street Group LLC increased its holdings in Co-Diagnostics by 314.1% during the 2nd quarter. Jane Street Group LLC now owns 166,254 shares of the company’s stock valued at $47,000 after purchasing an additional 126,105 shares during the period. Virtu Financial LLC grew its position in shares of Co-Diagnostics by 393.8% in the 3rd quarter. Virtu Financial LLC now owns 126,524 shares of the company’s stock worth $44,000 after buying an additional 100,901 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Co-Diagnostics by 40.4% during the fourth quarter. Geode Capital Management LLC now owns 449,148 shares of the company’s stock valued at $81,000 after buying an additional 129,158 shares during the period. 14.99% of the stock is owned by institutional investors.

About Co-Diagnostics

Co-Diagnostics, Inc is a molecular diagnostics company headquartered in Salt Lake City, Utah, known for its proprietary CoPrimer™ technology. Founded in 2016, the company focuses on the design, development and distribution of molecular diagnostic test kits for the detection of infectious diseases, genetic mutations and other health-relevant biomarkers. Its core platform leverages patented cooperative primers, which are engineered to enhance specificity, sensitivity and cost-effectiveness compared to conventional PCR-based assays.

Through its in-house manufacturing and global supply chain partnerships, Co-Diagnostics produces a range of real-time polymerase chain reaction (qPCR) kits, reagents and customized assay development services.